Posted : Mon, 06 Dec 2010 02:32:41 GMT Author : EpiCept Corporation: 777 Old Saw Mill River Road Tarrytown, NY 10591 Robert W. Cook (914) 606-3500 firstname.lastname@example.org Investors: Lippert/Heilshorn & Associates Kim Sutton Golodetz (212) 838-3777 email@example.com or Bruce Voss (310) Category : Press Release News Alerts by Email ( click here ) Press Release News | Home
TARRYTOWN, N.Y. - (Business Wire) EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) announced today that an abstract for Ceplene® was presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 4-7, 2010, in Orlando, Florida. The Abstract, Number 2182 (Poster Board II-62) was presented today between 6:00 PM-8:00 PM in Hall A3/A4. The Abstract is entitled “Incremental Benefit of Histamine Dihydrochloride When Added to Interleukin-2 for Remission Maintenance in Acute Myeloid Leukemia: A Bayesian Meta-analysis” and was authored by Scott M. Berry, PhD and Kristine R. Broglio, MS, Berry Consultants, LLC, College Station, TX; Donald A. Berry, PhD, Berry Consultants, LLC and Division of Quantitative Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX.